실적분석 2026년 8월 3일

Clorox ($CLX) Q4 2026 Earnings Analysis — Adjusted EPS and Revenue Both Beat Expectations, Modest After-Hours Gain

Earnings Scorecard

Revenue: $1.948 billion (–2% YoY, estimate $1.914 billion) ✅ Beat

EPS (earnings per share): $1.66 on an adjusted basis (–42% vs. $2.87 a year earlier, estimate $1.65) ✅ Beat

Guidance: Newly issued — FY2027 adjusted EPS $5.70–$6.00, revenue +13–14%

Stock reaction: +0.48% after-hours ($98.73) — as of 06:45 KST, 08-04

The Positives

Above consensus: Adjusted EPS of $1.66 and revenue of $1.948 billion both exceeded expectations

GOJO acquisition complete: Completed in April 2026, the GOJO acquisition has pushed the health and hygiene portfolio to over half of revenue

Annual growth roadmap: FY2027 organic sales +3.5–4.5%, adjusted EPS $5.70–$6.00

Clorox is a consumer-products company whose portfolio spans essential household brands such as bleach, trash bags, and cat litter. While this quarter's headline numbers looked weak versus the prior-year period, adjusted results landed slightly above the bar the market had already set in ($1.65 adjusted EPS and $1.914 billion revenue). GAAP diluted EPS was $1.34 (down 50% from $2.34 a year earlier, note: prior year stated as $2.68 in report), with net income attributable to Clorox common shareholders of $163 million.

Strategically, the GOJO acquisition — which brought the Purell brand — lifted health and wellness revenue 16% year over year, and management said the global health and hygiene portfolio now accounts for more than half of total revenue. The U.S. ERP cutover has also been completed, wrapping up a five-year digital investment, while the international segment delivered revenue growth of 4% and adjusted operating income growth of 17%, showing relative resilience.

The Negatives

Sharp organic sales decline: Q4 organic sales –13%, with the ERP compare impact accounting for roughly 13.5 percentage points

Margin pressure: Gross margin of 41.3%, down 520bp year over year

Core segments weak: Household –18% and Lifestyle –17%, with adjusted operating income down 56% and 60%, respectively

As the company itself acknowledged, a large portion of the shortfall is a base effect from retailers building inventory ahead of the ERP transition in the year-ago quarter. That compare alone is estimated to have weighed on EPS by about $0.90, and excluding it, health and wellness organic sales would actually have grown, management said. Even after stripping out the compare, however, higher raw materials, manufacturing, and logistics costs, along with step-up costs from revaluing GOJO inventory, weighed on margins.

Household (bags, wraps, cat litter, and grilling) and Lifestyle (food, water filtration, and natural personal care) saw particularly pronounced volume declines, exacerbated by shipment pull-forward pressures from Q3. Full-year FY2026 operating cash flow was $612 million, down 38% from $981 million a year earlier, mainly due to payments related to the termination of the Glad joint venture. Interest expense also climbed sharply to $55 million for the quarter, versus $22 million a year earlier.

What Management Said

Management emphasized that Q4 results met its own expectations and that, despite consumer and macro pressures, the foundation has been strengthened through the GOJO acquisition, the completion of the U.S. ERP cutover, and enhanced digital capabilities. At the same time, leadership drew a clear line that FY2027 will likely continue to see cost volatility and value-seeking consumers, striking a measured rather than purely optimistic tone.

The newly issued FY2027 outlook calls for revenue growth of 13–14% (including roughly 9.5 percentage points from GOJO), organic sales growth of 3.5–4.5%, gross margin of approximately 42%, and adjusted EPS of $5.70–$6.00. A key point is that a meaningful portion of the organic growth (more than 3.5 percentage points) reflects lapping the prior-year ERP inventory depletion compare, and because inflation and unfavorable mix are expected to offset cost savings, a full margin recovery is unlikely. The market is likely to read this as a "meets expectations + compare recovery story," but there is plenty of room to question how quickly underlying demand is actually recovering.

Market Reaction and What to Watch Next

With results largely in line with both company guidance and consensus, there was no major surprise. The modest beats on revenue and adjusted EPS, combined with a roadmap pointing to FY2027 revenue and earnings growth driven by GOJO contributions and the ERP compare, are factors that reduced downside risk. On the other hand, the double-digit organic sales decline, the steep drop in gross margin, and ongoing weakness in Household and Lifestyle left too little fuel for a strong rally, which is consistent with the muted modestly positive after-hours reaction.

It will be important to confirm whether underlying organic sales — excluding the ERP compare — stay positive in the coming quarter.

The pace of GOJO (Purell) integration, health and hygiene synergies, and the run-off of acquisition-related costs (roughly a $0.29 impact in FY2027) will be key to margin recovery.

It remains to be seen whether the company's guided gross margin of approximately 42% and A&P spend of around 10% of revenue hold up amid real-world demand and pricing competition.